ArticleBiochemistry and biophysics reports2025
Hepatoma-derived growth factor and non-coding RNA network in ovarian cancer patients.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian cancer (OC) remains the most lethal gynecologic malignancy due to late diagnosis and limited effective biomarkers. Hepatoma-derived growth factor (HDGF) has emerged as an oncogene implicated in tumor progression, yet its regulation and clinical potential in OC remains underexplored. Recent evidence suggests that long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) may modulate oncogenic pathways through competing endogenous RNA (ceRNA) networks. Methods and results: Fifty ovarian cancer and fifty normal ovarian tissue samples were analyzed for HDGF, miR-345-5p, and LINC00839 expression using qRT-PCR. Bioinformatic tools were employed to predict RNA-RNA interactions and reconstruct a ceRNA network. Statistical analyses examined expression correlations and diagnostic performance via ROC curve. HDGF and LINC00839 were significantly upregulated, while miR-345-5p was downregulated in OC tissues (p < 0.001). HDGF expression correlated positively with LINC00839 (r = 0.70) and inversely with miR-345-5p (r = -0.58), suggesting a regulatory axis where LINC00839 sponges miR-345-5p to derepress HDGF. Elevated HDGF levels were associated with larger tumor size, advanced FIGO stage, and metastasis. ROC analysis revealed that HDGF serum level (AUC = 0.88) has promising diagnostic potential, albeit lower than CA-125 and HE4. Conclusion: Our study highlights the LINC00839-miR-345-5p-HDGF axis as a key regulatory network in ovarian cancer. HDGF may serve as a clinically relevant biomarker for disease progression, while LINC00839 and miR-345-5p represent promising therapeutic targets. These findings provide a foundation for future investigations into ceRNA-based diagnostics and treatments in OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.